ES2306771T3 - Un metodo de terapia celular para tratamiento de tumores. - Google Patents

Un metodo de terapia celular para tratamiento de tumores. Download PDF

Info

Publication number
ES2306771T3
ES2306771T3 ES02742493T ES02742493T ES2306771T3 ES 2306771 T3 ES2306771 T3 ES 2306771T3 ES 02742493 T ES02742493 T ES 02742493T ES 02742493 T ES02742493 T ES 02742493T ES 2306771 T3 ES2306771 T3 ES 2306771T3
Authority
ES
Spain
Prior art keywords
peripheral blood
cells
blood monocytes
nnapc
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02742493T
Other languages
English (en)
Inventor
Juli Degraw
Ann Moriarty
Didier J Leturcq
Michael R Jackson
Per A Peterson
Marja Heiskala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of ES2306771T3 publication Critical patent/ES2306771T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)

Abstract

Un método para preparar una suspensión CD8 + para su uso en el tratamiento de un sujeto con cáncer que comprende: a. preparar una línea celular presentadora de antígenos no natural (nnAPC), donde dicha nnAPC presenta de cuatro a diez moléculas peptídicas diferentes asociadas con dicho cáncer simultáneamente donde dichas moléculas peptídicas tienen cada una aproximadamente de seis a doce aminoácidos de longitud; b. estimular las células CD8 + cosechadas a partir de dicho sujeto o donante adecuado con dicha línea celular nnAPC; c. añadir dichas células CD8 + a un medio que contiene una citoquina, seleccionada del grupo que consiste en IL-2, IL-7 o medio de crecimiento acondicionado (CGM), donde dichas citoquinas se pueden utilizar individualmente o combinadas; d. mezclar monocitos de sangre periférica no suspendidos, o alternativamente, monocitos de sangre periférica empobrecidos en CD8 recogidos de dicho sujeto o donante adecuado con aproximadamente 1 a 50 mug/ml de uno de dichos péptidos que dicha nnAPC presenta simultáneamente; e. irradiar dicha suspensión de monocitos de sangre periférica con una dosis suficiente de radiación gamma necesaria para evitar la proliferación de estas células en la suspensión, excepto los monocitos de sangre periférica deseados; f. aislar los monocitos de sangre periférica adherentes; g. cargar dichos monocitos de sangre periférica adherentes con aproximadamente 1 mg/ml a 50 mug/ml de cada uno de los péptidos mencionados; y h. combinar dichas células CD8 + con dichos monocitos de sangre periférica adherentes en una proporción de aproximadamente diez células CD8 + por monocito de sangre de periférica.
ES02742493T 2001-02-20 2002-02-19 Un metodo de terapia celular para tratamiento de tumores. Expired - Lifetime ES2306771T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27025201P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
ES2306771T3 true ES2306771T3 (es) 2008-11-16

Family

ID=23030546

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02742493T Expired - Lifetime ES2306771T3 (es) 2001-02-20 2002-02-19 Un metodo de terapia celular para tratamiento de tumores.
ES14187466.9T Expired - Lifetime ES2643582T3 (es) 2001-02-20 2002-02-19 Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14187466.9T Expired - Lifetime ES2643582T3 (es) 2001-02-20 2002-02-19 Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer

Country Status (21)

Country Link
US (2) US20030077248A1 (es)
EP (3) EP2016930B1 (es)
JP (3) JP2006510567A (es)
KR (2) KR100971266B1 (es)
CN (1) CN1571834B (es)
AT (1) ATE396691T1 (es)
BR (1) BR0207399A (es)
CA (2) CA2698079C (es)
DE (1) DE60226853D1 (es)
DK (1) DK2016930T3 (es)
EA (1) EA013944B1 (es)
ES (2) ES2306771T3 (es)
HU (1) HUP0402656A3 (es)
IL (3) IL157366A0 (es)
MX (1) MXPA03007503A (es)
NO (1) NO334885B1 (es)
NZ (1) NZ527683A (es)
PL (1) PL206976B1 (es)
PT (1) PT1377251E (es)
WO (1) WO2002065992A2 (es)
ZA (1) ZA200307327B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
EP2371854B1 (en) * 2001-03-09 2014-05-07 Board Of Regents, The University Of Texas System Induction of tumor immunity by variants of folate binding protein
EP1482963A4 (en) * 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes
EP1645183B1 (en) 2003-06-16 2013-03-13 Kyushu University, National University Corporation Process for producing human-origin immunocompetent cell
JP2005139118A (ja) * 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2014127296A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN103667189B (zh) * 2013-09-24 2015-10-28 上海宇研生物技术有限公司 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016196506A1 (en) 2015-05-29 2016-12-08 Galena Biopharma, Inc. PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
WO2025171250A1 (en) * 2024-02-08 2025-08-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nyeso1 tcr for t-cell therapy and methods of use
CN121472152B (zh) * 2026-01-09 2026-04-03 无锡市第二人民医院 细胞药物及其在膀胱癌药物的药效评价方法及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4473642A (en) 1981-04-29 1984-09-25 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US4407945A (en) 1981-04-29 1983-10-04 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4992367A (en) 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
CA2069541C (en) 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5487974A (en) 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6017719A (en) 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US5759783A (en) 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997032970A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
IL126843A (en) * 1996-05-23 2007-06-17 Scripps Research Inst Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
JP2002500872A (ja) * 1998-01-26 2002-01-15 ジェンザイム・コーポレーション 免疫エフェクター細胞ハイブリッド
WO1999054345A1 (en) 1998-04-21 1999-10-28 Thomas Jefferson University Cd8 antagonists
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ES2261197T3 (es) 1999-04-16 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Metodo para la deteccion de celulas t especificas de antigeno.
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
EP1263928B1 (en) * 2000-02-11 2007-09-26 Dana-Farber Cancer Institute, Inc. Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids
US20030165483A1 (en) * 2000-07-10 2003-09-04 Ulrich Zimmermann Method for the modification of biological cells
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.

Also Published As

Publication number Publication date
US20090305418A1 (en) 2009-12-10
KR100962544B1 (ko) 2010-06-14
CN1571834B (zh) 2013-03-20
WO2002065992A2 (en) 2002-08-29
KR20030077029A (ko) 2003-09-29
EA013944B1 (ru) 2010-08-30
KR100971266B1 (ko) 2010-07-20
EP1377251A2 (en) 2004-01-07
EP2848255A1 (en) 2015-03-18
CN1571834A (zh) 2005-01-26
HUP0402656A2 (hu) 2005-03-29
IL219223A0 (en) 2012-06-28
EP2016930A2 (en) 2009-01-21
NO20033674L (no) 2003-10-17
DE60226853D1 (de) 2008-07-10
EP2848255B1 (en) 2017-08-23
IL219223B (en) 2018-05-31
HK1058485A1 (en) 2004-05-21
MXPA03007503A (es) 2004-10-15
WO2002065992A3 (en) 2003-02-13
US20030077248A1 (en) 2003-04-24
CA2438754C (en) 2014-10-07
JP2010222352A (ja) 2010-10-07
NZ527683A (en) 2006-06-30
CA2698079C (en) 2015-01-13
IL157366A (en) 2013-04-30
PL206976B1 (pl) 2010-10-29
NO20033674D0 (no) 2003-08-19
JP2006510567A (ja) 2006-03-30
KR20090061081A (ko) 2009-06-15
PL369971A1 (pl) 2005-05-02
DK2016930T3 (en) 2014-12-08
NO334885B1 (no) 2014-06-30
JP5634415B2 (ja) 2014-12-03
EP2016930A3 (en) 2009-09-02
EP1377251B1 (en) 2008-05-28
HUP0402656A3 (en) 2012-03-28
EA200300815A1 (ru) 2004-06-24
ES2643582T3 (es) 2017-11-23
IL157366A0 (en) 2004-02-19
HK1208376A1 (en) 2016-03-04
US9222071B2 (en) 2015-12-29
ATE396691T1 (de) 2008-06-15
EP2016930B1 (en) 2014-10-15
CA2438754A1 (en) 2002-08-29
EP1377251A4 (en) 2006-01-11
PT1377251E (pt) 2008-08-05
ZA200307327B (en) 2005-03-30
JP2012097117A (ja) 2012-05-24
CA2698079A1 (en) 2002-08-29
BR0207399A (pt) 2004-10-26

Similar Documents

Publication Publication Date Title
RU2766457C2 (ru) Способы и композиции для лечения рака с помощью антисмысла
Thamm Canine cancer: strategies in experimental therapeutics
ES2236719T3 (es) Metodo para fabricar un medicamento para el tratamiento de la inmunodeficiencia secundaria.
EP3352783B1 (en) Vaccine comprising immuno-isolated cells producing an immunomodulator
AU2018244221A1 (en) ANK and IL-12 compositions and methods
Glick et al. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo
Chang et al. Current status of adoptive immunotherapy of cancer
EA016168B1 (ru) Способ получения т-клеточной популяции и ее применение
Tatsumi et al. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity
ES2270643B1 (es) Un procedimiento de identificacion de una modificacion final de al menos un parametro biologico usando celulas vivas sujetas a estres y celulas vivas no sujetas a este mismo estres.
US4926861A (en) Method for in vivo treatment of tumorous tissues on body surfaces
Okamoto et al. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro
Hirokawa et al. Restoration of impaired immune functions in aging animals: V. Long-term immunopotentiating effects of combined young bone marrow and newborn thymus grafts
Salomon et al. Cryopreserved aortic homografts contain viable smooth muscle cells capable of expressing transplantation antigens
Chen et al. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
DE60114780T2 (de) Hyperthermie und immunotherapie für leukaemien, lymphomas und feste tumore
Mulé Dendritic cell‐based vaccines for pancreatic cancer and melanoma
EP2147682B1 (en) Vaccination with immuno-isolated cells producing an immunomodulator
Yaron et al. UVB irradiation of human-derived peripheral blood lymphocytes induces apoptosis but not T-cell anergy: additive effects with various immunosuppressive agents
US20260041378A1 (en) Methods of and devices/apparatus for detecting, triggering, and using cell-to-cell communication
Juillard et al. Intralymphatic infusion of autochthonous tumor cells in canine lymphoma
JP7430914B2 (ja) がんの治療のための医薬組成物
Jablonska et al. Effect of IL-15 on the secretion of IL-1β, IL-1Ra and sIL-1RII by PMN from cancer patients
Chagnon et al. Murine renal cell carcinoma: evaluation of a dendritic‐cell tumour vaccine
Zeng et al. Cis-delivering releasable IL-15 superagonist enhances antitumor immunity in cold tumors by invigorating preexisting CD25+ CD8+ T cells